Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness of different Dialectical Behavior Therapy DBT approaches for individuals with Borderline Personality Disorder BPD within public mental health services in Chile. The study compares a 12-week DBT skills training group with a 24-week quasi-standard DBT program and treatment as usual. This trial aims to understand whether the shorter DBT skills training can be as effective as the longer standard treatment in reducing suicidal and self-harming behaviors. The study involves three groups an enhanced 13-week DBT skills training program including orientation, weekly skills groups, phone check-ins, emergency coaching, and team meetings a 24-week standard DBT program with preparatory individual sessions, weekly skills groups, individual therapy, phone coaching during office hours, and consultation meetings and treatment as usual consisting of monthly or biweekly individual psychotherapy sessions at community mental health centers. These interventions are delivered in routine public healthcare settings and aim to assess different treatment durations and structures. Participants will be assessed using many tools to track changes in suicidal behavior, psychopathology, borderline symptoms, emotion regulation, dissociation, depression, trauma, functioning, personality traits, substance use, disability, quality of life, social isolation, satisfaction, costs, and stress. Assessments occur at baseline, weekly during intervention, and at 3 and 6 months post-start. The main outcome measures focus on suicidal severity ratings at baseline, 3 months, and 6 months. The total study duration is about 6 months per participant, with ongoing monitoring and evaluation throughout.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.